Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022
Daiana Stolz,
Maria Gabriella Matera,
Paola Rogliani,
Maarten van den Berge,
Eleni Papakonstantinou,
Reinoud Gosens,
Dave Singh,
Nicola Hanania,
Mario Cazzola,
Anke-Hilse Maitland-van der Zee,
Laura Fregonese,
Alexander G. Mathioudakis,
Jørgen Vestbo,
Maia Rukhadze,
Clive P. Page
Affiliations
Daiana Stolz
Clinic of Pulmonary Medicine, Department of Internal Medicine, Medical Center University of Freiburg, Freiburg, Germany
Maria Gabriella Matera
Unit of Pharmacology, Department of Experimental Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
Paola Rogliani
Unit of Respiratory Medicine, Department Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy
Maarten van den Berge
Groningen Research Institute for Asthma and COPD, and Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Eleni Papakonstantinou
Clinic of Pulmonary Medicine, Department of Internal Medicine, Medical Center University of Freiburg, Freiburg, Germany
Reinoud Gosens
Groningen Research Institute for Asthma and COPD, and Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Dave Singh
Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK
Nicola Hanania
Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
Mario Cazzola
Unit of Respiratory Medicine, Department Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy
Anke-Hilse Maitland-van der Zee
Department of Pulmonary Medicine, University of Amsterdam, Amsterdam University Medical Centres, Amsterdam, The Netherlands
Laura Fregonese
European Medicines Agency, London, UK
Alexander G. Mathioudakis
Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK
Jørgen Vestbo
Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK
Maia Rukhadze
Center of Allergy and Immunology, Teaching University Geomedi LLC, Tbilisi, Georgia
Clive P. Page
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK
Pharmacological management of airway obstructive diseases is a fast-evolving field. Several advances in unravelling disease mechanisms as well as intracellular and molecular pathways of drug action have been accomplished. While the clinical translation and implementation of in vitro results to the bedside remains challenging, advances in comprehending the mechanisms of respiratory medication are expected to assist clinicians and scientists in identifying meaningful read-outs and designing clinical studies. This European Respiratory Society Research Seminar, held in Naples, Italy, 5–6 May 2022, focused on current and future developments of the drugs used to treat asthma and COPD; on mechanisms of drug action, steroid resistance, comorbidities and drug interactions; on prognostic and therapeutic biomarkers; on developing novel drug targets based on tissue remodelling and regeneration; and on pharmacogenomics and emerging biosimilars. Related European Medicines Agency regulations are also discussed, as well as the seminar's position on the above aspects.
